Sol-Gel Technologies Common Stock Net 2016-2024 | SLGL
Sol-Gel Technologies common stock net from 2016 to 2024. Common stock net can be defined as the value of common equity ownership.
Sol-Gel Technologies Annual Common Stock Net
(Millions of US $) |
| 2023 |
$1 |
| 2022 |
$1 |
| 2021 |
$1 |
| 2020 |
$1 |
| 2019 |
$1 |
| 2018 |
$1 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$0 |
Sol-Gel Technologies Quarterly Common Stock Net
(Millions of US $) |
| 2024-06-30 |
$1 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$1 |
| 2023-09-30 |
$1 |
| 2023-06-30 |
$1 |
| 2023-03-31 |
$1 |
| 2022-12-31 |
$1 |
| 2022-09-30 |
$1 |
| 2022-06-30 |
$1 |
| 2022-03-31 |
$1 |
| 2021-12-31 |
$1 |
| 2021-09-30 |
$1 |
| 2021-06-30 |
$1 |
| 2021-03-31 |
$1 |
| 2020-12-31 |
$1 |
| 2020-09-30 |
$1 |
| 2020-06-30 |
$1 |
| 2020-03-31 |
$1 |
| 2019-12-31 |
$1 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
$1 |
| 2019-03-31 |
$1 |
| 2018-06-30 |
$1 |
| 2018-03-31 |
$1 |
| 2017-12-31 |
|
| 2017-09-30 |
$0 |
| 2017-06-30 |
$0 |
| 2016-12-31 |
$0 |
| 2015-12-31 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.020B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
